ReviewExpert opinion on investigational drugs2018
Gabapentin for the treatment of alcohol use disorder.
Review in Expert opinion on investigational drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review.Alcoholism, clinical and experimental research · 2019Pooled it
- A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Identifying responders to gabapentin for the treatment of alcohol use disorder: an exploratory machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Trial
- Reward, relief, and habit drinking profiles in treatment seeking individuals with an AUD.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Trial
- N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A preliminary randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.Alcoholism, clinical and experimental research · 2019Trial
- High Prevalence of Unhealthy Alcohol Use Among Persons with HIV, Viral Non-suppression and Any Alcohol Use in Mbarara, Uganda: A Brief Report.AIDS and behavior · 2026Article
- Comparative effectiveness of gabapentin and pregabalin on reduction in alcohol use: A nationwide observational cohort study.medRxiv : the preprint server for health sciences · 2026Article
- Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.Current gastroenterology reports · 2025Review
- Rethinking trazodone for insomnia in alcohol use disorder.Addiction science & clinical practice · 2025Article
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Multi-modal neuroimaging reveals differences in alcohol-cue reactivity but not neurometabolite concentrations in adolescents who drink alcohol.Drug and alcohol dependence · 2024Article
- A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder.Brain sciences · 2024Review
- Review
- Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.Clinical therapeutics · 2023Review
- Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians.Clinical liver disease · 2023Article
- Alcohol use disorder treatment delivered outside hepatology clinic.Clinical liver disease · 2023Article
- Dissecting operant alcohol self-administration using saccharin-fading procedure.Neuropsychopharmacology reports · 2023Article
- Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.International journal of environmental research and public health · 2023Review
- Cell therapy for neuropathic pain.Frontiers in molecular neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
introductionAlcohol misuse is the fifth leading risk factor for premature death and disability worldwide. Fewer than 10% of afflicted Americans receive pharmacological treatment for alcohol use disorder. Gabapentin is a calcium channel GABAergic modulator that is widely used for pain. Studies showing reduced drinking and decreased craving and alcohol-related disturbances in sleep and affect in the months following alcohol cessation suggest therapeutic potential for alcohol use disorder. Areas covered: Human laboratory and clinical studies assessing gabapentin for alcohol use disorder are reviewed. Data were obtained by searching for English peer-reviewed articles on PubMed, reference lists of identified articles, and trials registered on clinicaltrials.gov. Additionally, the mechanism of action of gabapentin specific to alcohol use disorder, and studies of gabapentin for alcohol withdrawal and non-alcohol substance use disorders are summarized. Expert opinion: Alcohol use disorder represents a challenge and large, unmet medical need. Evidence from single-site studies lend support to the safety and efficacy of gabapentin as a novel treatment for alcohol use disorder, with unique benefits for alcohol-related insomnia and negative affect, relative to available treatments. Proprietary gabapentin delivery systems may open a path to pivotal trials and registration of gabapentin as a novel treatment for alcohol use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.